CVM

Insider Trades

Name	Value	Action	Price	Current Price
Kersten Geert RDirector, Officer: Chief Executive Officer $360k300k shares BuyMay 14, 2026 $1.20 --
Kersten Geert RDirector, Officer: Chief Executive Officer $119k100k shares BuyMay 13, 2026 $1.19 --
Kersten Geert RDirector, Officer: Chief Executive Officer $200k38k shares BuyJan 22, 2026 $5.26 --
Kersten Geert RDirector, Officer: Chief Executive Officer $50k8.4k shares BuyDec 4, 2025 $5.96 --
Kersten Geert RDirector, Officer: Chief Executive Officer $200k29.2k shares BuyJul 25, 2025 $6.85 --
Watson Robert EugeneDirector $20k2.9k shares BuyJul 25, 2025 $6.85 --

News

businesswire.comCEL-SCI Announces Closing of Offeringbusinesswire.comJun 16

businesswire.comCEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategybusinesswire.comJun 16

businesswire.comCEL-SCI Corporation Announces Pricing of Offeringbusinesswire.comJun 14

businesswire.comCEL-SCI and Saudi Amarox to Conduct Signing Ceremony at BIO 2026 for Strategic Agreement to Advance Commercialization and Distribution of Multikine® in Saudi Arabiabusinesswire.comJun 12

businesswire.comCEL-SCI Reports Fiscal Second Quarter 2026 Resultsbusinesswire.comMay 18

Trade CVM

About CEL-SCI Corporation

CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.

CEO: Geert R. Kersten
IPO Date: Dec 8, 1983

Market Data

Open: $1.13
High: $1.17
Low: $1.02
Volume: 522.9K
Avg Volume: 409.6K
52W High: $13.48
52W Low: $0.89

Valuation

Market Cap: $7.1M
Enterprise Value: $14M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $-17B
Revenue: $0
Net Income: $-25M
Cash: $11M
Debt: $9.4M

Events

EarningsAug 17